A rumor regarding Zevra Therapeutics (ZVRA) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Shares of Zevra are up 49c, or 5%, to $9.77 in Thursday morning trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics: Strong Buy Rating Amid Impressive Q2 Results and Strategic Growth Potential
- Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability
- Zevra Therapeutics’ Earnings Call: Optimism Amid Challenges
- CoreWeave reports Q2 beat, Gildan to acquire Hanesbrands: Morning Buzz
- Zevra Therapeutics: Strong Buy Rating Amid U.S. Growth and EU Market Potential